Johnson & Johnson Stock: Apollo Offers 20 Billion - Börse Express
Article excerpt
Highlighted: the sentence this signal was extracted from
Johnson & Johnson could soon divest its orthopedics division DePuy Synthes - not via an IPO, but through a multi-billion dollar sale to a financial investor. According to a report, Apollo Global Management is negotiating an acquisition of the business at a valuation of almost 20 billion Dollars. A deal could be concluded within a few weeks.That DePuy Synthes is leaving the group is no surprise. J&J had already announced the spin-off in October 2025, as part of a broader portfolio realignment towards higher-growth healthcare segments. CFO Joseph Wolk confirmed in July that various separation options were being explored to create shareholder value. Originally, a timeframe of 18 to 24 months for a spin-off as an independent publicly listed company was discussed, with a target completion by mid-2027. Now an alternative is emerging: the direct sale to private equity. Several financial investors are said to have expressed interest in the business, so another bidder could still emerge.For Apollo, the transaction would be its largest healthcare investment to date and a significant expansion in the medical technology sector. Bloomberg Intelligence's in-house analysis even assumes a higher value - approximately 28 billion Dollars including debt, noticeably above the currently discussed sum. The spread between the rumored 20 billion Dollars and the higher analyst estimate shows: There...
Keep reading with a free account
The rest of this article, and every signal for Apollo Global Management, is in your free account.
